Tours Cedex 9

• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Efficacy of dalbavancin in osteoarticular infections associated with hip, knee and shoulder prostheses PRO-DALBA Ended recruitment
  2024-518183-12-00 10 2022-03-07 prosthetic joint infections
• OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma … Ended recruitment
  2024-512634-15-00 9 2022-01-05 Patients with untreated mantle cell lymphoma
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA … Ended recruitment
  2023-506241-30-00 5 2021-11-30 Advanced Colorectal Cancer with KRAS G12C Mutation
• FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated … Ended recruitment
  2024-513936-80-00 4 2021-11-12 elderly patients (> 70 years) with CLL or SLL
• A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat … Ended recruitment
  2023-507698-16-00 5 2021-10-14 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Ended recruitment
  2024-512028-12-00 4 2021-03-19 Advanced ROS1-positive non-small cell lung cancer
• Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended recruitment
  2024-515944-22-00 4 2021-01-19 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC … Ended recruitment
  2023-507475-21-00 10 2021-01-18 Lung Cancer, Non-Small Cell
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera M … Ended recruitment
  2024-514468-26-00 9 2020-12-04 Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), O
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung … Ended recruitment
  2024-511185-37-00 6 2020-11-03 Completely resected stage I or IIA non-squamous non-small cell lung ca
• A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast … Ended recruitment
  2024-514733-38-00 5 2020-11-03 Unresectable locally-advanced or metastatic HER2+ breast cancer
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat … Ended recruitment
  2023-503421-19-00 5 2020-08-26 Urothelial cancer
• MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended recruitment
  2024-512269-14-00 5 2020-01-27 GIant cell Arteritis
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel … Ended recruitment
  2023-505219-19-00 9 2019-09-03 Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM
• OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN A … Ended recruitment
  2024-516048-24-00 4 2019-06-19 CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST

Showing 145–168 of 208 trials